These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29368591)

  • 41. Immunogenicity and protective immunity against otitis media caused by pneumococcus in mice of Hib conjugate vaccine with PsaA protein carrier.
    Chen Z; Guo R; Xu J; Qiu C
    Front Med; 2016 Dec; 10(4):490-498. PubMed ID: 27650380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hib antibody responses in infants following diphtheria, tetanus, acellular pertussis, and conjugated Haemophilus influenzae type b (Hib) combination vaccines with decreasing amounts of tetanus toxoid.
    Bernstein HH; Seyferth ER
    Vaccine; 2017 Dec; 35(48 Pt B):6707-6711. PubMed ID: 29054729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
    Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
    Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae type b alone or conjugated to tetanus toxoid in 18- to 23-month-old children.
    Claesson BA; Trollfors B; Lagergard T; Taranger J; Bryla D; Otterman G; Cramton T; Yang Y; Reimer CB; Robbins JB
    J Pediatr; 1988 May; 112(5):695-702. PubMed ID: 3361379
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
    Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
    Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and safety of two doses of catch-up immunization with Haemophilus influenzae type b conjugate vaccine in Indian children living with HIV.
    Arya BK; Bhattacharya SD; Sutcliffe CG; Saha MK; Bhattacharyya S; Niyogi SK; Moss WJ; Panda S; Das RS; Mallick M; Mandal S
    Vaccine; 2016 Apr; 34(19):2267-74. PubMed ID: 26988256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.
    Heath PT; Booy R; Azzopardi HJ; Slack MP; Bowen-Morris J; Griffiths H; Ramsay ME; Deeks JJ; Moxon ER
    JAMA; 2000 Nov; 284(18):2334-40. PubMed ID: 11066183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
    Pace D; Snape M; Westcar S; Hamaluba M; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
    Pediatr Infect Dis J; 2007 Nov; 26(11):1057-9. PubMed ID: 17984816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation.
    Molrine DC; Guinan EC; Antin JH; Wheeler C; Parsons SK; Weinstein HJ; McGarigle C; Blanding P; Phillips NR; Ciamarra A; George S; Ambrosino DM
    Bone Marrow Transplant; 1996 Jun; 17(6):1149-55. PubMed ID: 8807128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The immunological response of Thai infants to haemophilus influenzae type B polysaccharide-tetanus conjugate vaccine co-administered in the same syringe with locally produced diphtheria-tetanus-pertussis vaccine.
    Kerdpanich A; Hutagalung Y; Watanaveeradej V; Bock HL; Steinhoffmd M
    J Med Assoc Thai; 2007 Jul; 90(7):1330-6. PubMed ID: 17710973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
    Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.
    Lee YC; Kelly DF; Yu LM; Slack MP; Booy R; Heath PT; Siegrist CA; Moxon RE; Pollard AJ
    Clin Infect Dis; 2008 Jan; 46(2):186-92. PubMed ID: 18171249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conjugate Haemophilus influenzae type b vaccines for sickle cell disease.
    Allali S; Chalumeau M; Launay O; Ballas SK; de Montalembert M
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD011199. PubMed ID: 30125338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine.
    Mäkelä PH; Käyhty H; Leino T; Auranen K; Peltola H; Ekström N; Eskola J
    Vaccine; 2003 Dec; 22(2):287-92. PubMed ID: 14615157
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine.
    Schmitt HJ; Maechler G; Habermehl P; Knuf M; Saenger R; Begg N; Boutriau D
    Clin Vaccine Immunol; 2007 Apr; 14(4):426-34. PubMed ID: 17287313
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine.
    Southern J; Crowley-Luke A; Borrow R; Andrews N; Miller E
    Vaccine; 2006 Jan; 24(2):215-9. PubMed ID: 16112255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and safety of LBVH0101, a new Haemophilus influenzae type b tetanus toxoid conjugate vaccine, compared with Hiberix™ in Korean infants and children: a randomized trial.
    Kim KH; Kim YK; Kim NH; Chang SH; Lee J; Park EA; Park SE; Eun BW; Lee H; Lee HJ
    Vaccine; 2012 Feb; 30(10):1886-94. PubMed ID: 22245607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunologic response to Hib tetanus toxoid conjugated vaccine coadministered with DTPa either mixed or in two separate injections in toddlers not primed with Hib vaccine.
    Meriste S; Jacquet JM; Willems P; Lutsar I
    Hum Vaccin; 2008; 4(1):31-5. PubMed ID: 18438103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.